A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.

Trial Details

NCT ID
NCT07607925
Phase
PHASE1 / PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • GSK5926371
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • New York, New York, United States|40.71427,-74.00597
  • Canton, Ohio, United States|40.79895,-81.37845
  • Heidelberg, Victoria, Australia|-37.75,145.06667
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated,
  • Has measurable disease,
  • Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication;
  • Has documented disease relapse, progression or disease refractory to the most recent line of therapy, per Lugano criteria.:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →